24/7 Market News Snapshot 30 April, 2025 – Regulus Therapeutics Inc. (NASDAQ:RGLS)

April 30, 2025

DENVER, Colo., 30 April, 2025 (www.247marketnews.com) – (NASDAQ:RGLS) are discussed in this article.
Regulus Therapeutics Inc. has garnered significant attention in the financial markets, with its stock soaring in pre-market trading at $7.889, marking a staggering 134.09% increase from its previous close of $3.370. This jump reflects robust investor sentiment, possibly fueled by news surrounding its recent merger agreement with Novartis AG. The transaction involves Novartis acquiring Regulus for an initial cash payment of $7.00 per share, representing a considerable 274% premium over Regulus’ average stock price over the past two months. The total value of this agreement could reach approximately $1.7 billion, contingent upon performance milestones for Regulus’ lead candidate, farabursen.

Jay Hagan, CEO of Regulus, expressed optimism about the merger, asserting the company’s mission to enhance patient outcomes, particularly for those suffering from autosomal dominant polycystic kidney disease (ADPKD). He highlighted that farabursen has the potential to be a first-in-class treatment, and with Novartis’ extensive global development capabilities, the company is well-positioned to deliver this therapy to patients with limited options.

Shreeram Aradhye, Chief Medical Officer of Novartis, reiterated the significance of farabursen in addressing the considerable need for effective treatments targeting the genetic causes of kidney failure. He emphasized the excitement within Novartis to continue advancing the investigational efforts initiated by Regulus.

The merger is scheduled for completion in the latter half of 2025, pending regulatory approvals and customary conditions. Regulus will function as an independent entity until the merger closes. The unanimous endorsement of the transaction by the Boards of Directors of both companies signals a strategic alignment that aims to strengthen patient care in vital therapeutic areas, marking a new chapter for Regulus as it integrates under Novartis.

Related news for (RGLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.